Table 1:
Characteristics of the entire GeRI cohort and by recruiting site
| Characteristics | GeRI | MSKCC | PM | UCSF | VUMC |
|---|---|---|---|---|---|
| (n=1316) | (n=752) | (n=266) | (n=31) | (n=267) | |
| Mean age at diagnosis (SD) | 65.24 (10.26) |
66.13 (10.52) |
64.60 (10.48) |
65.30 (9.71) |
63.33 (9.01) |
| Sex n(%) | |||||
| Male | 659 (50.1) |
353 (46.9) |
142 (53.4) |
12 (38.7) |
152 (56.9) |
| Female | 657 (49.9) |
399 (53.1) |
124 (46.6) |
19 (61.3) |
115 (43.1) |
| Self-reported race | |||||
| White | 914 (69.5) |
469 (64.0) |
167 (62.8) |
31 (100) |
246 (92.1) |
| Asian | 89 (6.8) |
34 (4.6) |
46 (17.3) |
- | 2 (0.7) |
| Black | 70 (5.3) |
41 (5.6) |
10 (3.8) |
- | 14 (5.2) |
| Other | 16 (1.2) |
20 (0.2) |
52 (4.4) |
- | 3 (1.1) |
| Missing | 227 (17.2) |
188 (25.6) |
31 (11.7) |
- | 2 (0.7) |
| Histology n(%) | |||||
| Adenocarcinoma | 949 (72.1) |
580 (77.1) |
193 (72.6) |
24 (77.4) |
152 (56.9) |
| Squamous cell carcinoma | 221 (16.8) |
111 (14.8) |
46 (17.3) |
5 (16.1) |
59 (22.1) |
| Other | 146 (11.1) |
61 (8.1) |
27 (10.2) |
2 (6.5) |
56 (21.0) |
|
Type of therapy n(%)
Anti PD-1/PD-L1 therapy |
1198 (91.0) |
671 (89.2) |
257 (96.6) |
31 (100.0) |
239 (89.5) |
| Anti PD-1/PD-L1 + Anti CTLA4 therapy | 118 (9.0) |
81 (10.8) |
9 (3.4) |
0 (0.0) |
28 (10.5) |
| IMC n(%) | |||||
| Yes | 55 (4.2) |
32 (4.3) |
13 (4.9) |
1 (3.2) |
9 (3.4) |
| No | 1261 (95.8) |
720 (95.7) |
253 (95.1) |
30 (96.8) |
258 (96.6) |
| Mean time in months to IMC (SD) | 9.85 (13.37) |
9.78 (13.42) |
11.07 (13.75) |
15.28 (-) |
8.19 (11.77) |
| Severe IMC* n(%) | |||||
| Yes | 32 (2.4) |
15 (2.0) |
10 (3.8) |
1 (3.2) |
6 (2.2) |
| No | 1261 (95.8) |
720 (95.7) |
253 (95.1) |
30 (96.8) |
258 (96.6) |
| Progression n(%) | |||||
| Yes | 999 (75.9) |
640 (85.1) |
177 (66.5) |
22 (71.0) |
160 (59.9) |
| No | 315 (23.9) |
112 (14.9) |
89 (33.5) |
8 (25.8) |
106 (39.7) |
| Missing | 2 (0.2) |
0 (0.0) |
0 (0.0) |
1 (3.2) |
1 (0.4) |
| Mean time in months to progression (SD) | 10.02 (13.44) |
10.11 (13.68) |
9.67 (11.13) |
27.07 (23.67) |
8.18 (11.74) |
| Overall survival n(%) | |||||
| Alive at last follow-up | 410 (31.2) |
262 (34.8) |
131 (49.2) |
17 (54.8) |
0 (0.0) |
| Deceased | 639 (48.6) |
490 (65.2) |
135 (50.8) |
14 (45.2) |
0 (0.0) |
| Missing | 267 (20.3) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
267 (100.0) |
| Mean time in months to death (SD) | 22.09 (17.81) |
21.71 (16.99) |
20.84 (18.57) |
43.37 (18.88) |
- |
*
The combined percentage does not add to 100 because mild-to-moderate grade IMC were excluded from this grouping. MSKCC, Memorial Sloan Kettering Cancer Center; PM, Princess Margaret Cancer Centre; UCSF, University of California San Francisco; VUMC, Vanderbilt University Medical Center; SD: Standard deviation; IMC: Immune checkpoint inhibitor-mediated colitis